Kornimate/medical-research-clean huggingface dataset:
study of denagliptin in subjects with type 2 diabetes mellitus (t2dm)

Conditions: Type 2 Diabetes Mellitus

Summary: gw823093 is a selective dpp-iv inhibitor and is being investigated as a once a day oral therapy. the purpose of the study is to evaluate the effectiveness, safety, and tolerability of 2 doses of gw823093, compared to placebo, taken once daily in patients with type 2 diabetes mellitus.


Eligibility criteria:
inclusion criteria: * type 2 diabetes mellitus treated with diet and exercise or oral anti-diabetic treatment * body mass index between 20 and 40 * females of childbearing potential must use adequate birth control. exclusion criteria: * subjects with previous use of insulin * type 1 diabetes * uncontrolled thyroid disease * history of drug or alcohol abuse in the past year * any other clinically significant disease.

Keywords: type 2 diabetes mellitus (t2dm) glycosylated hemoglobin (hba1c) denagliptin diabetes treatment glycemic control
clinical application and mechanism of cord blood mononuclear cells in the treatment of ischemic bowel disease

Conditions: Ischemic Bowel Disease

Summary: ischemic bowel disease, also known as ischemic bowel disease (ibd), is a type of disease that causes the blood supply to a certain intestinal segment to be reduced or stopped by various reasons such as hypovolemia, shock or recent abdominal surgery, resulting in insufficient blood supply to the intestinal wall, and causing a series of pathological changes in the intestine. human umbilical cord blood mononuclear cells (hucb-mnc) can be economically and conveniently isolated from human cord blood. the hucb-mnc obtained from the isolation of human umbilical cord blood contains a variety of stem cells, such as hematopoietic stem cells, endothelial stem cells, etc. a number of previous studies have confirmed that hucb-mnc can improve the occurrence of ischemic bowel disease through immunomodulatory and tissue repair. these characteristics make hucb-mnc a cell with great potential to treat ischemic diseases.


Eligibility criteria:
inclusion criteria: * age is not limited, gender is not limited. meet the diagnostic criteria for ischemic bowel disease and clearly diagnose inpatient patients with ischemic bowel disease. * diagnosis and diagnosis (standard) in line with the "2011 chinese medical. * association gerontology branch organization of relevant experts jointly wrote the diagnosis and treatment of ischemic bowel disease in the elderly in china": 1. acute mesenteric ischemia (ami): clinical manifestations are acute and severe abdominal pain, symptoms do not match the severity of signs, and signs are often not obvious. abdominal x-ray may show "finger marks" and balloon signs. ct shows no visualization of the superior mesenteric artery or intraluminal filling defect. arteriography is helpful in diagnosis, and intestinal mucosal pathology is dominated by ischemic changes, such as in patients with vasculitis, thrombosis, and vascular embolism. 2. chronic mesenteric ischemia (cmi): clinical symptoms are recurrent abdominal pain, chronic disease capacity, emaciation, no tenderness in the abdomen, and vascular murmurs can often be heard in the upper abdomen. imaging tests such as arteriography, cta, and mra can help confirm the diagnosis of cmi. it is mainly based on clinical symptoms and advanced imaging tests. 3. ischemic colitis (ic): manifested as unexplained abdominal pain, bloody stool, diarrhea or abdominal acute abdomen, which can be diagnosed with colonoscopy and angiography if necessary. exclusion criteria: * the diagnosis does not conform to the "2011 cases of diagnosis and treatment recommendations for ischemic bowel disease in the elderly in china jointly written by relevant experts organized by the geriatrics branch of the chinese medical association"; * exclude those with serious diseases of other organs; * patients with other diseases such as gastrointestinal tumors and inflammatory bowel diseases cannot be excluded.
a study to describe the kidney cancer patient population treatment, and results in the hospital district of southwest finland.

Conditions: Renal Cell Cancer; Renal Cell Carcinoma; Cancer of Kidney; Cancer of the Kidney; Kidney Cancer; Kidney Neoplasms; Renal Cancer

Summary: the purpose of the study is to find out how patients with advanced kidney cancer have been treated in the hospital district of southwest finland over time.


Eligibility criteria:
inclusion criteria: for the characteristic group: * diagnosis of renal cell carcinoma (international classification of diseases 10th revision \[icd\]-10:64) during 01 january 2010 and 31 december 2021 for the mrcc group: * icd-10 diagnosis code for metastasis (c77\*-c79\*), or * american joint committee on cancer (ajcc) stage 4, or ajcc stage data potentially not available for all patients * visit to oncologist (specialty code 65) with rcc as main diagnosis, or in finland, the icd-10 codes for metastatic disease are rarely used. in contrast, rcc patients visit oncologist, when and only when disease metastasises and therefore, the visit can be used as a proxy to a metastatic disease * initiation of treatment for mrcc exclusion criteria: for the characteristic group: * prevalent mrcc patients (i.e. diagnosis of metastatic rcc before 01 january 2010) * prevalent mrcc patients (i.e. diagnosis of rcc before 01 january 2010) if there is no records of metastatic disease during 2010-2021 for the mrcc group: * prevalent patients with mrcc (i.e. diagnosis of metastatic rcc before 01 january 2010) * patients without treatment for mrcc

Keywords: advanced/ metastatic rcc (mrcc) real world evidence registry based study non-interventional study axitinib sunitinib pazopanib cabozantinib nivolumab sorafenib everolimus ipilimumab
vitamin d repletion in chronic kidney disease

Conditions: Chronic Kidney Disease

Summary: the reason for doing this research is that people with kidney disease often suffer from heart disease. why this happens is not fully known. a possible cause may be high blood levels of a substance made by bacteria called "endotoxin". the blood levels of this substance are high in people with medium-level kidney disease. we want to know if replacing normal amounts of vitamin d can help lower the levels of this substance. we also want to know if replacing normal amounts of vitamin d is associated with other changes that may help heart disease. we hope that our research will help figure out if levels of this substance can be lowered by replacing normal amounts of vitamin d. normal subjects are enrolled to have a 'control' set for comparison purposes.

your participation in this study requires: * 4 visits to the outpatient clinic (including 1 screening visit) * providing a blood sample (less than 5 tablespoons) and a urine sample at each visit * taking a test to measure how leaky your gut is. this test requires that you drink a small amount of liquid (about 4 ounces) and then collect your urine for 6 hours after drinking the liquid.

Eligibility criteria:
inclusion criteria: inclusion criteria for healthy volunteers * males and post-menopausal females, between the age of 50 -80. * vitamin d 25-oh level less than 20 ng/ml inclusion criteria for medium-level kidney function volunteers * males and post-menopausal females, between the age of 50 -80. * chronic kidney disease stage 3 * vitamin d 25-oh level less than 20 ng/ml exclusion criteria: * serum calcium level \>10.5 mg/dl * serum phosphorus level \> 5.5 mg/dl * serum pth level \< 35 pg/ml * active infection including hiv, hepatitis b or c * history of recent acute infection ( within 1 month) * gastrointestinal disease resulting in significant gi dysfunction or malabsorption * hgb\< 10 g/dl * current use of coumadin * current use of vitamin d \>400 iu/day * current use of systemic steroids or other immunosuppressants * history of malignancy not in remission (\>6 months) * history of current ethanol abuse or illicit drug use * history of significant emotional disorder within the past 5 years * participation in an investigational drug study within one month of screening * have any other condition, which in the opinion of the investigator, should prohibit the participation in the study

Keywords: vitamin d3 repletion levels of endotoxin intestinal permeability accelerated atherosclerosis
progress: management of moderate aortic stenosis by clinical surveillance or tavr

Conditions: Aortic Stenosis, Calcific; Aortic Valve Stenosis

Summary: this study objective is to establish the safety and effectiveness of the edwards sapien 3 / sapien 3 ultra / sapien 3 ultra resilia transcatheter heart valve systems in subjects with moderate, calcific aortic stenosis. following completion of enrollment, subjects will be eligible for enrollment in the continued access phase of the trial.

this is a prospective, randomized, controlled, multicenter study. subjects will be randomized to either transcatheter aortic valve replacement (tavr) with the sapien 3 / sapien 3 ultra /sapien 3 ultra resilia thv or clinical surveillance.

Eligibility criteria:
key inclusion criteria: 1. 65 years of age or older at time of randomization 2. moderate aortic stenosis 3. subject has symptoms or evidence of cardiac damage/dysfunction 4. the subject or subject's legal representative has been informed of the nature of the study, agrees to its provisions, and has provided written informed consent. key exclusion criteria: 1. native aortic annulus size unsuitable for the thv 2. anatomical characteristics that would preclude safe transfemoral placement of the introducer sheath or safe passage of the delivery system 3. aortic valve is unicuspid or non-calcified 4. bicuspid aortic valve with an aneurysmal ascending aorta \> 4.5 cm or severe raphe/leaflet calcification 5. pre-existing mechanical or bioprosthetic aortic valve 6. severe aortic regurgitation 7. prior balloon aortic valvuloplasty to treat severe as 8. lvef \< 20% 9. left ventricular outflow tract calcification that would increase the risk of annular rupture or significant paravalvular leak post-tavr 10. cardiac imaging evidence of intracardiac mass, thrombus, or vegetation 11. coronary or aortic valve anatomy that increases the risk of coronary artery obstruction post-tavr

Keywords: transcatheter aortic valve replacement (tavr) sapien 3 sapien 3 ultra sapien 3 ultra resilia moderate aortic stenosis aortic stenosis transcatheter heart valve
telerehabilitation upper extremity for neurological disorders

Conditions: Multiple Sclerosis; Stroke

Summary: the aims of the present study were to: * investigate the feasibility of using a therapeutic gaming system (rehab@home), based on kinect, to augment upper extremity neurorehabilitation services. * provide preliminary evidence of clinical efficacy of the approach in increasing arm activity and health related quality of life of persons post stroke or with ms. main results suggest that the serious games approach was positively received in terms of user experience and motivation to use, with the participants showing also improvements in functional abilities of the treated arm.

the objective of this pilot study was to assess the feasibility of using a therapeutic gaming system (rehab@home), based on kinect, to augment upper extremity neurorehabilitation services. a secondary objective was to provide preliminary evidence of clinical efficacy of the approach in increasing arm activity and health related quality of life of persons post stroke or with multiple sclerosis (ms). a pilot single-blind randomized controlled trial was carried out in an inpatient and ambulatory care at a rehabilitation center. twenty persons with multiple sclerosis (n=16) or chronic poststroke (n=4) receiving rehabilitation at the center, able to flex shoulder and elbow at least 45 degrees, participated in the study. an intervention group received serious games-based upper extremity therapy for a total of 12 sessions (4-5 sessions, lasting 40 minutes, per week) and the control played the same amount of time with commercial exergames of the wii. both groups received their usual rehabilitation services as well as game playing.

Eligibility criteria:
inclusion criteria: * persons post stroke or with ms with resultant upper extremity motor deficits. * range of motion of shoulder and elbow equal or higher than 45 degrees. * able to comprehend and follow directions. exclusion criteria: * wearing pace maker * comorbidities affecting arm use * not able to comprehend and follow directions

Keywords: arm rehabilitation serious games stroke multiple sclerosis
exploring blood plasma metabolomics: unraveling the metabolic landscape in treatment-resistant adolescent depression

Conditions: Psychiatric Disorder; Major Depressive Disorder; Metabolic Disorder

Summary: this study contributes new evidence for the identification of adolescent trd and sheds light on differing pathophysiologies by delineating distinct plasma metabolic profiles between adolescent trd and fedn-mdd.


Eligibility criteria:
inclusion criteria: fedn-mdd： 1. age 12-18 years 2. meet the diagnostic criteria for mdd according to the dsm-5 3. first-episode and drug-naive 4. hamd-17 score \> 17 trd: 1. age 12-18 years 2. meet the diagnostic criteria for mdd according to the dsm-5 3. hamd-17 score \> 13 4. currently or previously taking a standard therapeutic dose of antidepressant for at least 6 weeks, and they had at least one historical failure to an antidepressant (reduction in depressive symptoms \<50%) hc: 1. age 12-18 years 2. hamd-17 score \< 7 3. hcs without a personal history of a mental illness or family history in a first-degree relative exclusion criteria: fedn-mdd、trd： 1. the presence or past history of severe medical, neurological or psychiatric disorders (other than mdd in patients) 2. anxiety comorbidity was not considered an exclusion criterion provided that mdd was the main diagnosis and the primary reason for seeking assistance 3. substance abuse, head trauma, or loss of consciousness 4. chronic physical diseases that significantly affect peripheral metabolism or neurological function 5. pregnant and lactating women hc: 1. the presence or past history of severe medical, neurological or psychiatric disorders 2. substance abuse, head trauma, or loss of consciousness 3. chronic physical diseases that significantly affect peripheral metabolism or neurological function 4. pregnant and lactating women

Keywords: adolescent mdd treatment-resistant depression metabolomic
the effect of dry needling of the gluteus medius muscle in patients with chronic low back pain

Conditions: Low Back Pain

Summary: the effectiveness of dry needling of the gluteus medius muscle in combination with active exercises will be examined compared with sham needling with active exercises in low back pain (lbp) patients.

objectives: to examine if dry needling in combination with active physiotherapy is more effective in reducing pain and increase activity of daily living, range of motion and muscle strength in patients with chronic low back pain compared to sham dry needling in combination with active physiotherapy. methods: the study will include individuals with non-specific lbp over 3 months. subjects will be divided randomly into two research groups, both will receive physiotherapy including mobility, strengthening and stretching exercises. intervention group, additionally to exercises, will receive dry needling to the gluteus medius muscle by inserting a needle to a trigger point until a visible involuntary twitch in the muscle appears. sham needling will be applied by needling with pre-cut and smoothed needles that will not penetrate the skin. both groups will receive two treatments per week and up to six treatments overall, evaluation will be performed before and after the series of treatments.

Eligibility criteria:
inclusion criteria: * main complaint of nonspecific lbp over a 3 month period * vas \> 3 at baseline exclusion criteria: * two or more of the following signs are present on physical examination: lower extremity weakness in a myotome distribution, decreased sensation in a dermatomal distribution, altered lower extremity deep tendon reflexes, pathological reflexes, a positive straight leg raise (slr) test, crossed slr or femoral nerve stretch test. * symptoms began immediately after a significant trauma (motor vehicle accident, fall from a height) and subjects were not been screened for possible fractures. * physical therapy or chiropractic treatment for lbp was provided during the 6 months prior to participation in the study or are currently being treated. * presence of contraindication for dry needling * pregnancy * past back or pelvic surgery
feasibility testing a meditation app for professionals working with youth in the legal system

Conditions: Anxiety; Depression; Burnout, Professional; Emotion Regulation

Summary: this feasibility clinical trial aims to assess the feasibility of implementing a 1-month app-based meditation program with officers in the juvenile legal system and other professionals working directly with legal-involved youth.

professionals working with legal-involved youth experience high levels of depression, anxiety, and workplace burnout. mindfulness meditation targets emotion regulation-which appears to be a common mechanism underlying depression, anxiety, and burnout-and it can be effectively delivered via smartphone app. this project will assess the feasibility of implementing a 1-month app-based meditation program with officers and other professionals working with legal-involved youth in cook county, which houses one of the nation's largest juvenile legal systems. the findings are intended to inform the development of a future, fully-powered hybrid effectiveness-implementation randomized controlled trial (rct).

Eligibility criteria:
inclusion criteria: * currently working with youth in the juvenile legal system or related juvenile services and programming * english speaking * able to understand and provide consent * at least 18 years old * have an android or apple smartphone
biology of cerebral arteriovenous malformations and prognosis of cerebral arteriovenous malformations

Conditions: Cerebral Arteriovenous Malformations; Ruptured or Unruptured Cerebral Arteriovenous Malformations

Summary: the cerebral arteriovenous malformations correspond to the formation of an entanglement of morphologically abnormal vessels called nidus, which shunt the blood circulation directly from the arterial circulation to the venous circulation. the cerebral arteriovenous malformations are an important cause of hemorrhagic stroke. the hypothesis is that cerebral haemorrhage associated with a cerebral arteriovenous malformations would come from peri-nidal micro-vessels, in connection with infiltration of leucocytes and / or defective maintenance of microvascular integrity by platelets.


Eligibility criteria:
inclusion criteria: * patient over 18 years old * patient with a cerebral avm for which an intervention (endovascular treatment or surgery) or only clinical monitoring * express consent to participate in the study and * children * free informed and express consent of both holders of the minor patient's parental authority, or, by way of derogation and only if the other holder of parental authority cannot give his or her consent within a time limit compatible with the methodological requirements specific to the conduct of the research with regard to its purposes, of one of the two holders of parental authority exclusion criteria: * patient benefiting from a legal protection measure * pregnant or breast feeding woman
botanical supplement muscle function and lean body mass

Conditions: Healthy Volunteers

Summary: purpose: to evaluate the acute and chronic effects of a botanical supplement on strength, muscle function, and lean body mass participants: the acute phase will include 30 participants, and the chronic phase will include 84 participants. all participants must be healthy recreationally active males between the ages of 18 and 35 years. procedures (methods): acute phase: participants will complete three testing visits as part of as part of a cross-over design, during which strength and muscle function will be assessed prior to and following consumption of a supplement. the experimental supplement is a blend of the botanical extracts; treatment arms will include a full dose (full; 350 mg capsule), half dose (half; 175 mg plus maltodextrin), or placebo (pla; maltodextrin). chronic phase: body composition, muscle cross-sectional area, a complete blood count and metabolic panel, subjective surveys, and strength will be measured prior to and following an 8-week supervised resistance training program, in conjunction with daily supplementation of full, half, or pla.


Eligibility criteria:
inclusion criteria: * recreationally active (1- 4 hours of exercise/ sports participation per week and no more than 1 hour of resistance training exercise per week) for the previous 12 weeks. * bmi \< 30 kg/m² * have not smoked in the past year. * participant has provided written and dated informed consent to participate in the study * participant is willing and able to comply with the protocol * participant is apparently healthy and free from disease, as determined by a health history questionnaire * participant agrees to abstain from caffeine, tobacco, alcohol, and exercise within 24 hours of testing visits exclusion criteria: * participant has not used any dietary supplements within 12 weeks prior to enrollment and will not begin supplementation during the study. potential supplements include but are not limited to beta-alanine, creatine, hmb, carnosine, taurine, androstenedione, dhea, whey protein, or a pre-workout supplement. * participant has gained or lost 10 lbs in the previous 2 months. * participant is currently enrolled in a separate clinical trial. * participant has participated in a clinical trial within the previous 2 months that includes modifications to their physical and/or diet. * participant has a known allergy or sensitivity to the placebo (maltodextrin) or active ingredients (rhodiola \& rhaptonicum) * participant consumes more than 8 cups (1 cup = 6 oz) of coffee per day on a regular basis * participant consumes more than 3 alcoholic drinks per day. * participant uses recreational drugs daily. * previous physical symptoms causing a physician to recommend you to refrain from exercise.

Keywords: botanical supplement performance-enhancing supplement
risk prediction for alzheimer dementia with brain imaging and genetics

Conditions: Alzheimer Dementia; Posttraumatic Stress Disorder; Traumatic Brain Injury

Summary: the purpose of this study is to learn about how trauma, posttraumatic stress disorder (ptsd), and mild traumatic brain injury that can occur during deployment affect the brain. the investigators also want to learn how ptsd and mild traumatic brain injury can affect the chance of developing alzheimer disease later in life. the investigators will study this by using magnetic resonance imaging and positron emission tomography scans to obtain pictures of the brain.


Eligibility criteria:
inclusion criteria: * age 18 to 65 * previously enrolled in studies of oef/oif veterans by the same investigators * free of implanted metal objects or mental shards in eyes * fluent in english and capable of consenting exclusion criteria: * axis i disorders other than major depressive disorder or ptsd * current substance abuse or lifetime substance dependence (other than nicotine) * high risk for suicide * claustrophobia * neurological disorders * learning disability or developmental delay * major medical conditions

Keywords: alzheimer dementia ptsd mri